Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Colorectal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 0 · 0%High 3 · 75%

Overall survival · people with metastatic CRC

Chemotherapy + bevacizumab leads to lower overall survival compared with chemotherapy (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.79 [0.7, 0.88]
4 studies · 1723 participants
High

Progression‐free survival · people with metastatic CRC

Chemotherapy + bevacizumab leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.67 [0.6, 0.75]
4 studies · 1723 participants
High

Tumour response · people with metastatic CRC

Chemotherapy + bevacizumab leads to higher overall tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.72 [1.23, 2.43]
4 studies · 1723 participants
High

Severe adverse effects · people with metastatic CRC

Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.07 [0.93, 1.25]
4 studies · 1708 participants
Low